Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
On Friday, China's National Medical Products Administration approved Eli Lilly And Co Tirzepatide for long-term weight management.
週五，中國國家醫療產品管理局批准禮來公司的開多巴肽用於長期體重管理。
It is suitable for long-term weight management of adults whose body mass index (BMI) meets the following requirements based on diet control and increased exercise: ≥28 kg/m2 (obese) or ≥24 kg/m2 (overweight) with at least one condition.
適用於長期減重管理的成年人，其身體質量指數（BMI）符合以下要求：通過飲食控制和增加運動達到≥28 kg / m2（肥胖）或≥24 kg / m2（超重）至少有一種病情控制。
Tirzepatide is known in the U.S. as Mounjaro for diabetes and Zepbound for weight loss.
Tirzepatide在美國被稱爲糖尿病藥物Mounjaro和減肥藥物Zepbound。
In May, the Chinese regulatory authority approved Tirzepatide in China to treat adults with type 2 diabetes.
今年五月，中國監管機構批准了Tirzepatide用於治療2型糖尿病的成年人。
In March, Eli Lilly revealed that it has identified bacteria and elevated impurity levels in products falsely claiming to be compounded versions of tirzepatide, the active ingredient in its widely-used diabetes medication Mounjaro and the weight loss treatment Zepbound.
三月份，Eli Lilly公司披露了一些產品，聲稱是合成型Tirzepatide的產品中存在細菌和雜質含量升高的虛假情況，這是其廣泛使用的糖尿病藥物Mounjaro和減肥治療Zepbound的活性成分。
In June, the Chinese National Medical Products Administration approved Novo Nordisk A/S's Wegovy (semaglutide) for long-term weight management.
六月份，中國國家藥品監督管理局批准了諾和諾德A / S的Wegovy（semaglutide）用於長期減重管理。
The approval comes at a crucial time, as the patent for semaglutide is set to expire in China in 2026.
申請的批准在一個關鍵時期到來，因爲semaglutide在中國的專利將於2026年到期。
Novo Nordisk also plans to limit the initial sales of its obesity treatment, Wegovy, in China. China's National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese.
諾和諾德還計劃限制其肥胖療法Wegovy在中國的初期銷售。據中國國家衛生健康委員會調查，超過14億人口中有一半以上超重或肥胖。
Price Action: LLY stock is up 1.19% at $859.01 during the premarket session at the last check on Friday.
價格走勢：截至上週五，LLY股票在盤前交易中漲1.19％，爲859.01美元。